Diabetic Retinopathy Market Research Report - Global Forecast till 2027

Global Diabetic Retinopathy Market Research Report: Information by Type (Non-proliferative and Proliferative), Treatment (Anti-VEGF Drugs, Laser Photocoagulation, Vitreoretinal Surgery, Steroid Injection), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/MED/4336-HCR | February 2021 | Region: Global | 95 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario


Diabetic Retinopathy Market is expected to register a CAGR of 11.9% during the forecast period of 2019 to 2025, with a market value of USD 1,309.73 Billion in 2018.


Eye diseases in diabetic patients are known as diabetic retinopathy. High blood sugar levels lead to the damage of the blood vessels in the retina. This results in the swelling and leakage of blood vessels or the blood vessels may close, thereby stopping blood from passing through. Sometimes, abnormal growth of new blood vessels is found on the retina. Blurred vision, dark or empty areas in your vision, spots, or dark strings floating in the vision (floaters), impaired color vision, and vision loss are various symptoms of diabetic retinopathy.


Vitreous hemorrhage, retinal detachment, glaucoma, and blindness are various complications associated with diabetic retinopathy, which may further lead to vision loss. The disease can be prevented by managing diabetes, controlling blood glucose levels, attention to vision changes, and many other methods in order to avoid vision impairment or vision loss.


The global diabetic retinopathy market is driven by factors such as the rising prevalence of diabetes and the increasing prevalence of blindness due to diabetes. Additionally, increasing geriatric population and increasing demand for diagnostic tests for the early diagnosis of diabetic retinopathy are anticipated to fuel the market growth. On the other hand, the lack of awareness about treatment is projected to hamper the growth of the market during the assessment period.


Moreover, major companies in the market are involved in strategic acquisitions, collaborations, product launch, expansion, and mergers to sustain their position in the market.


Segmentation


The Global Diabetic Retinopathy Market has been segmented based on type, treatment, end-user, and region.


The diabetic retinopathy market, based on type, has been segmented into non-proliferative and proliferative.


The diabetic retinopathy market, based on treatment, has been segmented into anti-VEGF drugs, laser photocoagulation, vitreoretinal surgery, and steroid injection.


The diabetic retinopathy market, based on end-user, has been segmented into hospitals, ambulatory surgical centers, and others.


The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diabetic retinopathy market in the Americas has further segmented into North America and Latin America, with the North American market divided into the US and Canada. The European diabetic retinopathy market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further the as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The diabetic retinopathy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diabetic retinopathy market in the Middle East & Africa has been divided into the Middle East and Africa.


Key Players


The key players in the Global Diabetic Retinopathy Market are F.Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Alimera Sciences, Ampio Pharmaceuticals Inc., Aurolab, Allergan PLC, Abbott Laboratories, and others.


Regional Market Summary


Global Diabetic Retinopathy Market Share by Region, 2018 (%)  Diabetic Retinopathy Market


Source: World Health Organization (WHO)


The diabetic retinopathy market in the Americas is expected to dominate the global diabetic retinopathy market due to the presence of major established players in the region and increasing R&D expenses.


Europe is expected to hold the second-largest position in the global diabetic retinopathy market. This can be attributed to the presence of a well-established healthcare system and an increased prevalence of diabetes.


Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing pool of population and increasing awareness about the products.


The diabetic retinopathy market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.


Global Diabetic Retinopathy Market, by Type



  • Non-Proliferative

  • Proliferative


Global Diabetic Retinopathy Market, by Treatment



  • Anti- VEGF Drugs

  • Laser Photocoagulation

  • Vitreoretinal Surgery

  • Steroid Injection


Global Diabetic Retinopathy Market, by End User



  • Hospitals

  • Ambulatory Surgical Centers

  • Others


Global Diabetic Retinopathy Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Research and development (R&D) companies

  • Diabetic retinopathy manufacturing companies

  • Government research institutes

  • Academic institutes and universities



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   11.9% (2020-207)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   type, treatment, end-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F.Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Alimera Sciences, Ampio Pharmaceuticals Inc., Aurolab, Allergan PLC, Abbott Laboratories
  Key Market Opportunities   lack of awareness about treatment
  Key Market Drivers

  • rising prevalence of diabetes
  • increasing prevalence of blindness due to diabetes
  • increasing geriatric population
  • increasing demand for diagnostic tests for the early diagnosis of diabetic retinopathy


  • Frequently Asked Questions (FAQ) :


    The valuation was USD 1,309.73 billion.

    The projected CAGR would be 11.9% during the forecast period of 2019 to 2025.

    The types included in the report are non-proliferative and proliferative.

    The treatments are vitreoretinal surgery, laser photocoagulation, anti-VEGF drugs, and steroid injection.

    Ambulatory surgical centers, hospitals, and others have been recorded as a part of the market report.

    Table Of Contents


    REPORT PROLOGUE

    MARKET INTRODUCTION


    2.1. Definition

    2.2. Scope Of The Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations


    RESEARCH METHODOLOGY


    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation


    MARKET DYNAMICS


    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities


    MARKET FACTOR ANALYSIS


    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power Of Suppliers

    5.1.2. Bargaining Power Of Buyers

    5.1.3. Threat Of New Entrants

    5.1.4. Threat Of Substitutes

    5.1.5. Intensity Of Rivalry

    5.2. Value Chain Analysis



    GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE


    6.1. Overview

    6.2. Non-Proliferative

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027

    6.3. Proliferative

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027


    GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT


    7.1. Overview

    7.2. Anti-VEGF Drugs

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027

    7.3. Laser Photocoagulation

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027

    7.4. Vitreoretinal Surgery

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027

    7.5. Steroid Injection

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027


    GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER


    8.1. Overview

    8.2. Hospitals

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027

    8.3. Ambulatory Surgical Centers

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027

    8.4. Others

    Market Estimates & Forecast, By Region, 2020–2027

    Market Estimates & Forecast, By Country, 2020–2027 9. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION

    9.1. Overview

    9.2. Americas

    9.2.1. North America

    9.2.1.1. US

    9.2.1.2. Canada

    9.2.2. Latin America

    9.3. Europe

    9.3.1. Western Europe

    9.3.1.1. Germany

    9.3.1.2. France

    9.3.1.3. Italy

    9.3.1.4. Spain

    9.3.1.5. UK

    9.3.1.6. Rest Of Western Europe

    9.3.2. Eastern Europe

    9.4. Asia-Pacific

    9.4.1. Japan

    9.4.2. China

    9.4.3. India

    9.4.4. Australia

    9.4.5. South Korea

    9.4.6. Rest Of Asia-Pacific

    9.5. Middle East & Africa

    9.5.1. Middle East

    9.5.2. Africa


    COMPANY LANDSCAPE


    10.1.1. Overview

    10.1.2. Competitive Analysis


    COMPANY PROFILES


    11.1. F. Hoffmann-La Roche AG

    11.1.1. Overview

    11.1.2. Product Overview

    11.1.3. Financial Overview

    11.1.4. Key Developments

    11.1.5. SWOT Analysis

    11.1.6. Key Strategies

    11.2. Regeneron Pharmaceuticals, Inc.

    11.2.1. Overview

    11.2.2. Product Overview

    11.2.3. Financial Overview

    11.2.4. Key Developments

    11.2.5. SWOT Analysis

    11.2.6. Key Strategies

    11.3. Alimera Sciences

    11.3.1. Overview

    11.3.2. Product Overview

    11.3.3. Financial Overview

    11.3.4. Key Developments

    11.3.5. SWOT Analysis

    11.3.6. Key Strategies

    11.4. Ampio Pharmaceuticals Inc.

    11.4.1. Overview

    11.4.2. Product Overview

    11.4.3. Financial Overview

    11.4.4. Key Developments

    11.4.5. SWOT Analysis

    11.4.6. Key Strategies

    11.5. Aurolab

    11.5.1. Overview

    11.5.2. Product Overview

    11.5.3. Financial Overview

    11.5.4. Key Developments

    11.5.5. SWOT Analysis

    11.5.6. Key Strategies

    11.6. Allergan PLC

    11.6.1. Overview

    11.6.2. Product Overview

    11.6.3. Financial Overview

    11.6.4. Key Developments

    11.6.5. SWOT Analysis

    11.6.6. Key Strategies

    11.7. Abbott Laboratories

    11.7.1. Overview

    11.7.2. Product Overview

    11.7.3. Financial Overview

    11.7.4. Key Developments

    11.7.5. SWOT Analysis

    11.7.6. Key Strategies

    11.8. Others


    APPENDIX


    12.1. References

    12.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL DIABETIC RETINOPATHY MARKET SYNOPSIS, 2020–2027

    TABLE 2 GLOBAL DIABETIC RETINOPATHY MARKET ESTIMATES AND FORECAST, 2020–2027 (USD MILLION)

    TABLE 3 GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 4 GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 5 GLOBAL DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 6 GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2020–2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 10 US: DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

    TABLE 11 US: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 12 US: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 13 CANADA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 14 CANADA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 15 CANADA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 16 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

    TABLE 17 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 18 LATIN AMERICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 19 EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 20 EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 21 EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 22 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 23 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 24 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 25 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 26 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 27 EASTERN EUROPE: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 28 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 29 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 30 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)

    TABLE 31 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY TYPE, 2020–2027 (USD MILLION)

    TABLE 32 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY TREATMENT, 2020–2027 (USD MILLION)

    TABLE 33 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET, BY END USER, 2020–2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE FOR GLOBAL DIABETIC RETINOPATHY MARKET

    FIGURE 3 MARKET DYNAMICS FOR GLOBAL DIABETIC RETINOPATHY MARKET

    FIGURE 4 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY TYPE, 2020 (%)

    FIGURE 5 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY TREATMENT, 2020 (%)

    FIGURE 6 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY END USER, 2020 (%)

    FIGURE 7 GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 8 NORTH AMERICA: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 9 EUROPE: DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 10 WESTERN EUROPE: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 11 ASIA-PACIFIC: DIABETIC RETINOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 MIDDLE EAST & AFRICA: DIABETIC RETINOPATHY MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 13 GLOBAL DIABETIC RETINOPATHY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 14 F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS

    FIGURE 15 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE

    FIGURE 16 F. HOFFMANN-LA ROCHE AG: GEOGRAPHICAL REVENUE

    FIGURE 17 REGENERON PHARMACEUTICALS, INC.: KEY FINANCIALS

    FIGURE 18 REGENERON PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

    FIGURE 19 REGENERON PHARMACEUTICALS, INC.: GEOGRAPHICAL REVENUE

    FIGURE 20 ALIMERA SCIENCES: KEY FINANCIALS

    FIGURE 21 ALIMERA SCIENCES: SEGMENTAL REVENUE

    FIGURE 22 ALIMERA SCIENCES: GEOGRAPHICAL REVENUE

    FIGURE 23 AMPIO PHARMACEUTICALS INC.: KEY FINANCIALS

    FIGURE 24 AMPIO PHARMACEUTICALS INC.: SEGMENTAL REVENUE

    FIGURE 25 AMPIO PHARMACEUTICALS INC.: GEOGRAPHICAL REVENUE

    FIGURE 26 AUROLAB: KEY FINANCIALS

    FIGURE 27 AUROLAB: SEGMENTAL REVENUE

    FIGURE 28 AUROLAB: GEOGRAPHICAL REVENUE

    FIGURE 29 ALLERGAN PLC: KEY FINANCIALS

    FIGURE 30 ALLERGAN PLC: SEGMENTAL REVENUE

    FIGURE 31 ALLERGAN PLC: GEOGRAPHICAL REVENUE

    FIGURE 32 ABBOTT LABORATORIES: KEY FINANCIALS

    FIGURE 33 ABBOTT LABORATORIES: SEGMENTAL REVENUE

    FIGURE 34 ABBOTT LABORATORIES: GEOGRAPHICAL REVENUE